HOUSTON--(BUSINESS WIRE)--DNAtrix Inc., a biotech company focusing on the development of oncolytic viruses for cancer, announced today that it has been awarded a product development grant for $10.8 million to fund the company’s clinical-stage program in glioblastoma—the most aggressive type of brain cancer. The grant from the Cancer Prevention and Research Institute of Texas (CPRIT) is entitled “Clinical development and commercialization of oncolytic adenovirus for treating malignant glioma.”
Help employers find you! Check out all the jobs and post your resume.
